gip and glp-1 receptor agonist The Emerging Role of Dual Agonists in Glycemic Management and Cardiovascular Risk Reduction Corrination of a GLP-1 Receptor
Description
doi: 10.1111/dom.12651 68 HeinlaKVasarESedmanTVolkeV
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al
The Employer Coverage Debate The big topic of conversation for plan sponsors in this arena centers around covering injectable GLP-1 drugs for weight loss and how to manage the associated costs
Yusta, B
The ADA notes that medication adjustments should be individualized based on the patient's glycemic control, with appropriate glucose monitoring during any interruption period
This concept of microdosing GLP-1s gained traction due to obesity drug shortages shortly after these new, highly effective medications were approved in 2021 and 2022
